Notice Number: NOT-HL-08-109
Release Date: January 10, 2008
National Heart, Lung, and Blood Institute (NHLBI), (http://www.nhlbi.nih.gov)
The purpose of this Notice is to announce the NHLBI’s intention to issue a Request for Applications (RFA) early in 2008 to fund up to six awards in fiscal year 2008 to identify unique molecular phenotypes of lung diseases that can potentially be used as pre-clinical phenotypes for early diagnosis, biomarkers for prognosis, or as phenotypes for re-defining major categories of lung diseases. The primary molecular phenotyping is to measure genome-wide gene expression at RNA levels in human samples. If possible, data from other omics approaches (e.g., genome-wide scanning for SNPs, copy number variations, or DNA methylation) should be integrated with RNA data in order to have better understanding of the findings from RNA expression.
Gene expression variations are complex and quantitative traits that are shaped by multiple and possibly interacting genetic and environmental factors. There are three major advantages of using molecular phenotype in the study of lung diseases. First, its unique pattern can serve as a pre-clinical phenotype (biomarker) for early diagnosis. Second, as the intermediate entity between genotypes and clinical phenotypes, the molecular phenotype provides the critical layer of information for the study of risk factors (genetic and environmental) and molecular mechanisms of lung diseases. Third, it is one of the ideal datasets to study gene function, gene-gene and gene-environment interactions, and human gene-regulatory networks.
This RFA will support investigators to design innovative strategies for genome-wide gene expression profiling for studies of lung diseases using primarily samples from existing or ongoing cohort or clinical trials studies. The molecular and clinical phenotyping data will be made available to the broad scientific community.
The receipt date for applications is projected to be in May of 2008.
This Notice encourages investigators with access to samples from studies of lung diseases, laboratory technology, data management and analysis capabilities, and resource infrastructure necessary to carry out the proposed program to begin to consider applying for this new RFA.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Interested parties may contact:
Weiniu Gan, Ph.D.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Room 10042, MSC 7952
Bethesda, MD 20892-7952
Telephone: (301) 435-0202
FAX: (301) 480-5577
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)